INDOCO vs SOLARA: Stock Comparison

INDOCO REMEDIES vs SOLARA ACTIVE PHA SCIUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

SOLARA ACTIVE PHA SCI is the larger company by market capitalisation. INDOCO REMEDIES shows a higher ROE, while SOLARA ACTIVE PHA SCI shows a lower P/E, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

INDOCO leads 3; SOLARA leads 8 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

INDOCOSOLARA

Valuation lens

What price are you paying?

Market CapContext only
₹2,421 Cr
₹3,077 Cr
P/E RatioSOLARA has the lower reading
445.9x
0x
P/B RatioSOLARA has the lower reading
2.67x
2.45x
EPSINDOCO has the higher reading
₹7.04
₹3.38
Book ValueContext only
₹100.98
₹260.24
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
SOLARA is the larger company
₹3,077 Cr vs ₹2,421 Cr
P/E Ratio
SOLARA has a lower P/E
0x vs 445.9x
P/B Ratio
SOLARA has a lower P/B
2.45x vs 2.67x
EPS
INDOCO has higher earnings per share
₹7.04 vs ₹3.38
Revenue Growth (TTM YoY)
SOLARA has faster revenue growth
41.9% vs 21.9%
Qtr Sales Growth
INDOCO has stronger quarterly sales growth
14.31% vs 0%
Qtr Profit Growth
SOLARA has stronger quarterly profit growth
-4% vs -20.51%
ROE
INDOCO has a higher ROE
-0.51% vs -0.58%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricINDOCOSOLARA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricINDOCOSOLARA
Live Price₹262.51₹639.15
Day Change-3.69%1.48%
Volume3.69 L3.97 L
52-Week High₹332.2₹712
52-Week Low₹162.19₹422
Distance from 52W High-20.98%-10.23%

Valuation

MetricINDOCOSOLARA
Market Cap₹2,421 Cr₹3,077 Cr
P/E Ratio445.9x0x
P/B Ratio2.67x2.45x
EPS₹7.04₹3.38
Book Value₹100.98₹260.24
Dividend Yield0%0%

Growth

MetricINDOCOSOLARA
Revenue Growth (TTM YoY)21.9%41.9%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth14.31%0%
Qtr Profit Growth-20.51%-4%

Profitability & Leverage

MetricINDOCOSOLARA
ROE-0.51%-0.58%
ROCE4.26%4.66%
Net Margin-5.31%-0.54%
Operating Margin4.57%6.36%
Debt to Equity0.64x0.49x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricINDOCOSOLARA
Promoter Holding58.86%41.93% 0.07 pp
FII Holding1.27% 0.33 pp11.52% 0.19 pp
DII Holding17.68% 0.47 pp3.74% 0.04 pp
Public Holding22.04% 0.14 pp42.81% 0.08 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: INDOCO REMEDIES and SOLARA ACTIVE PHA SCI.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.